Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Lexaria Bioscience Corp. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 24, 2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
| Nevada | 000-52138 | 20-2000871 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer |
| incorporation) | Identification No.) |
| 156 Valleyview Road, Kelowna, BC Canada | V1X 3M4 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (250) 765-6424
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))
| Item 3.02 | Unregistered Sales of Equity Securities |
On March 24, 2017 Lexaria Bioscience Corp. (the “Company” or “Lexaria”) announced that it has it has received US$32,503.90 from the exercise of stock options and warrants previously granted. The stock options and warrants were exercised at the price of US$0.2273, for a total of 143,000 common shares being issued. All warrants and options are being exercised by third parties who are neither officers nor directors of the Company.
Following issuance of these common shares, Lexaria will have 56,901,479 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from this option and warrant exercise. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- 2 -
| Item 7.01 | Regulation FD Disclosure |
A copy of the news release announcing that Lexaria has received US$32,503.90 from the exercise of stock options and warrants previously granted is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press Release dated March 24, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
| /s/ Chris Bunka | |
| Chris Bunka | |
| CEO, Principal Executive Officer |
Date: March 24, 2017